NVNO

enVVeno Medical Corporation

$6.45

-5.84%
SectorHealthcareIndustryMedical DevicesCountryUnited States

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Source: Yahoo Finance
AI summary

Price & performance

1M-13.7%
3M-36.7%
YTD-45.1%
1Y-72.4%
52-week range—
Beta1.41
Full chart and returns against a benchmark

Q-Score

27/ 100

Quality against peers; 50 is the peer median.

Growth28
Risk39
Performance25
Valuation28
Profitability30
Leverage61
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$19.5M
Net margin—
Historical fundamentals

Red flags in filings

1active red flag
Auditor changeApr 21, 2025
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

NVNOIndustryP/E—29.61P/S—3.49EV/EBITDA—18.38P/B0.273.39PEG——
Dividend yield0.00%
Every valuation metric